Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics

Journal of Neuro-Oncology

Volumn 125, Issue 1, 2015, Pages 91-102

  St Coeur, Patrick Denis ^a   Poitras, Julie J ^a   Cuperlovic Culf, Miroslava ^b   Touaibia, Mohamed ^a   Morin, Pier Jr ^a  

^a UNIVERSITÉ DE MONCTON   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Cancer diagnosis; Cancer therapeutics; Glioblastoma multiforme; Lomeguatrib; Metabolomics; Temozolomide

Indexed keywords

ACONITIC ACID; ADENOSINE; ALANINE; ARGININE; CHOLINE; CITRIC ACID; CREATINE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCEROPHOSPHATE; HISTIDINE; INOSITOL; ISOCITRIC ACID; ISOLEUCINE; LEUCINE; LOMEGUATRIB; METHIONINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHORYLCHOLINE; PROLINE; SERINE; SUCCINIC ACID; TAURINE; TEMOZOLOMIDE; THREONINE; TRYPTOPHAN; UNINDEXED DRUG; VALINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; PURINE DERIVATIVE; TRITIUM; TUMOR SUPPRESSOR PROTEIN;

AMINO ACID METABOLISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CELL VIABILITY; CITRIC ACID CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOBLASTOMA MULTIFORME CELL LINE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLITE; METABOLOMICS; PRIMARY TUMOR; UPREGULATION; ANALOGS AND DERIVATIVES; BRAIN TUMOR; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; PURINES; TRITIUM; TUMOR SUPPRESSOR PROTEINS;

EID: 84942990204     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1899-6     Document Type: Article

References (57)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
2. Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319–331
3. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU (1992) Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550–4553
4. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947
5. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387
6. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110
7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
8. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287–291
9. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
10. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6-alkylguanine–DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 51:167–223
11. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189–4199
12. Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z, King A, Miller A, Waller S, Leung H, Margison GP, Middleton MR (2010) Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res 16:743–749
13. Taspinar M, Ilgaz S, Ozdemir M, Ozkan T, Oztuna D, Canpinar H, Rey JA, Sunguroğlu A, Castresana JS, Ugur HC (2013) Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Tumour Biol 34:1935–1947
14. Nicholson JK, Connelly J, Lindon JC, Holmes E (2002) Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 1:153–161
15. Wishart DS (2008) Applications of metabolomics in drug discovery and development. Drugs R D 9(5):307–322
16. Johnson CH, Gonzalez FJ (2012) Challenges and opportunities of metabolomics. J Cell Physiol 227:2975–2981
17. Cuperlovic-Culf M, Culf AS, Morin P Jr, Touaibia M (2013) Application of metabolomics in drug discovery, development and theranostics. Curr Metabol 1:41–57
18. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, Van Meir EG (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469–479
19. Lee ES, Ko KK, Joe YA, Kang SG, Hong YK (2011) Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells. Oncol Lett 2:115–121
20. Cuperlovic-Culf M, Touaibia M, St-Coeur P-D, Poitras J, Morin P Jr, Culf AS (2014) Metabolic effects of known and novel HDAC and SIRT inhibitors in glioblastomas independently or combined with temozolomide. Metabolites 4:807–830
21. Cuperlovic-Culf M, Ferguson D, Culf A, Morin P Jr, Touaibia M (2012) 1H NMR metabolomics analysis of glioblastoma subtypes: correlation between metabolomics and gene expression characteristics. J Biol Chem 287:20164–20175
22. 1H NMR metabolomics analysis of the effect of dichloroacetate and allopurinol on breast cancers. J Pharm Biomed Anal 93:77–85
23. Morin P Jr, Ferguson D, LeBlanc LM, Hébert MJ, Paré AF, Jean-François J, Surette ME, Touaibia M, Cuperlovic-Culf M (2013) NMR metabolomics analysis of the effects of 5-lipoxygenase inhibitors on metabolism in glioblastomas. J Prot Res 12:2165–2176
24. Savorani F, Tomasi G, Engelsen SB (2010) Icoshift: a versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson 202:190–202
25. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116–5121
26. Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37:D603–D610
27. Bobola MS, Berger MS, Silber JR (1995) Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosurea in human brain tumor-derived cell lines. Mol Carcinog 13:81–88
28. Mrugula MM, Chamberlain MC (2008) Mechanisms of disease: temozolomide and glioblastoma—look to the future. Nat Clin Pract Oncol 5:476–486
29. Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN (2009) Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys 75:212–219
30. de Saldanha da Gama Fischer J, Costa Carvalho P, da Fonseca CO, Liao L, Degrave WM, da Gloria da Costa Carvalho M, Yates JR, Domont GB (2011) Chemo-resistant protein expression pattern of glioblastoma cells (A172) to perillyl alcohol. J Proteome Res 10:153–160
31. Clemons M, Kelly J, Watson AJ, Howell A, McElhinney RS, McMurry TBH, Margison GP (2005) O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumor MCF7 cells and xenografts. Br J Cancer 93:1152–1156
32. Watson AJ, Middleton MR, McGown G, Thorncrofts M, Ranson M, Hersey P, McArthur G, Davis ID, Thomson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP (2009) O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer 10:1250–1256
33. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96:766–776
34. Kitange GJ, Carlson BL, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James CD, Sarkaria JN (2009) Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol 11:281–291
35. Ye ZC, Sontheimer H (1999) Glioma cells release excitotoxic concentrations of glumatamate. Cancer Res 59:4383–4391
36. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7:1010–1015
37. Kokkinakis DM, von Wronski MA, Vuong TH, Brent TP, Schold SC Jr (1997) Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells. Br J Cancer 5:779–788
38. Choi C, Ganji SK, DeBerardinis RJ, Dimitrov IE, Pascual JM, Bachoo R, Mickey BE, Malloy CR, Maher EA (2011) Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors. Magn Reson Med 66:609–618
39. Locasale JW, Melman T, Song S, Yang X, Swanson KD, Cantley LC, Wong ET, Asara JM (2012) Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma. Mol Cell Proteomics 11(M111):014688
40. Bauer DE, Harris MH, Plas DR, Lum JJ, Hammerman PS, Rathmell JC, Riley JL, Thompson CB (2004) Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J 18:1303–1305
41. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, Sugihara E, Onishi N, Yamamoto T, Yanagawa H, Suematsu M, Saya H (2012) Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 72:1438–1448
42. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W, Sun D (2007) Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 59:495–505
43. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11:1672–1682
44. Puig T, Aguilar H, Cufi S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamu B, Lopez-Rodriguez ML, Urruticoechea A, Colomer R (2011) A novel inhibitor of fatty acid synthase shows activity against HER2+ against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res 13:R131
45. Somashekar BS, Kamarajan P, Danciu T, Kapila YL, Chinnaiyan AM, Rajendiran TM, Ramamoorthy A (2011) Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. J Proteome Res 10:5232–5241
46. He XH, Li WT, Gu YJ, Yang BF, Deng HW, Yu YH, Peng WJ (2013) Metabonomic studies of pancreatic cancer response to radiotherapy in a mouse xenograft model using magnetic resonance spectroscopy and principal components analysis. World J Gastroenterol 19:4200–4208
47. Wei S, Liu L, Zhang J, Bowers J, Gowda GA, Seeger H, Fehm T, Neubauer HJ, Vogel U, Clare SE, Raftery D (2013) Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol Oncol 7:297–307
48. Rocha CR, Garcia CC, Vieira DB, Quinet A, de Andrade-Lima LC, Munford V, Belizário JE, Menck CF (2014) Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis 5:e1505
49. Tonigold M, Rossmann A, Meinold M, Bette M, Märken M, Henkenius K, Bretz AC, Giel G, Cai C, Rodepeter FR, Beneš V, Grénman R, Carey TE, Lage H, Stiewe T, Neubauer A, Werner JA, Brendel C, Mandic R (2014) A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels. J Cancer Res Clin Oncol 140:1689–1704
50. Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S (2014) Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res 20:5756–5767
51. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, Tan Y, Schold SC (2001) Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 61:4017–4123
52. Najim N, Podmore ID, McGown A, Estlin EJ (2009) Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines. Anticancer Res 29:3103–3108
53. Al-Saffar NM, Marshall LV, Jackson LE, Balarajah G, Eykyn TR, Agliano A, Clarke PA, Jones C, Workman P, Pearson AD, Leach MO (2014) Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3 K inhibition in pediatric glioblastoma. PLoS One 9:e103835
54. Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Maelandsmo GM, Engebraten O, Gribbestad IS, Bjørkøy G (2013) Metabolic biomarkers for response to PI3 K inhibition in basal-like breast cancer. Breast Cancer Res 15:R16
55. Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM (2013) HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells. PLoS One 8:e62610
56. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM (2012) Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3 K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol 14:315–325
57. Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, McCormick JE, Margison GP (2000) O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 85:248–252